NRX Pharmaceuticals
Yahoo Finance • 7 days ago
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Tilray Brands Global Push is Paying Off as International Cannabis Growth Drove Record Q3 Revenue Charlotte’s Web Strengthened Balance Sheet as British American Tobacco Deepened Stake Amid Strategic Growth Pu... Full story
Yahoo Finance • 20 days ago
NRx Pharmaceuticals Q4 Earnings Call Highlights
NRx Pharmaceuticals logo 5 Biotech stocks tapping into unmet mental health treatment needs NRx Pharmaceuticals (NASDAQ:NRXP) executives used the company’s fourth-quarter 2025 results call to outline what they described as a “pivotal and... Full story
Yahoo Finance • 20 days ago
NRx Pharmaceuticals Wraps Virtual Annual Meeting, Eyes Pivotal 2025 Earnings Call Ahead
NRx Pharmaceuticals logo Key Points 2025 described as "extraordinarily pivotal": NRx said it is "in the FDA" with at least one drug it hopes could be approved this year and is operating revenue-generating clinics treating patients daily.... Full story
Yahoo Finance • 23 days ago
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
Featured Companies Include FreeCast (NASDAQ:CAST), KLED.ai, Lantern Pharma (NASDAQ:LTRN), and BlackBarn Restaurant NEW YORK CITY, NY / ACCESS Newswire / March 21, 2026 / New to The Street, one of the longest-running U.S. and international... Full story
Yahoo Finance • last month
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
The bipolar depression market is anticipated to increase during the forecast period (2026–2036), owing to the rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics... Full story
Yahoo Finance • last month
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the scien... Full story
Yahoo Finance • 4 months ago
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal response achieved by Transcranial Magnetic Stimulation (TMS).NRx has amended its Investigational New Drug filing f... Full story
Yahoo Finance • 4 months ago
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is “substantially complete” and received for review. Assigned GDUFA goal date is July 29, 2026.NRx has applied to FDA for use of KETAFREE™ as a proprietary product name,... Full story
Yahoo Finance • 4 months ago
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a corporate update confere... Full story
Yahoo Finance • 4 months ago
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference
WILMINGTON, Del., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, the “Company”, “NRx”), a clinical-stage biopharmaceutical company and HOPE Therapeutics, an interventional psychiatry network owned by NRx, toda... Full story
Yahoo Finance • 5 months ago
NRx Pharmaceuticals outlines rapid clinic expansion and targets 6 or more locations by year-end 2025 amid new depression treatment advances
Earnings Call Insights: NRx Pharmaceuticals (NRXP) Q3 2025 MANAGEMENT VIEW * Matthew Duffy, Chief Business Officer & Co-CEO of Hope Therapeutics, opened the call stating, "Since the beginning of the third quarter, NRx has made transfor... Full story
Yahoo Finance • 5 months ago
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NRx has refiled its Abbreviated New Drug Application for KETAFREE™ (preservative free ketamine), received supportive correspondence from FDA, and expects Q2 2026 GDUFA date.HOPE Therapeutics is now operating three revenue-generating facili... Full story
Yahoo Finance • 5 months ago
Here are the major earnings before the open Monday
Major earnings expected before the bell on Monday include: * XPeng (XPEV [https://seekingalpha.com/symbol/XPEV]) * JinkoSolar Holding Co., Ltd. (JKS [https://seekingalpha.com/symbol/JKS]) * Luckin Coffee (OTCPK:LKNCY [https://seekin... Full story
Yahoo Finance • 5 months ago
Pre-Market Earnings Report for November 17, 2025 : HTHT, ARMK, YMM, JJSF, JKS, CRGO, ARBE, NRXP, IGC, VRME
The following companies are expected to report earnings prior to market open on 11/17/2025. Visit our Earnings Calendar for a full list of expected earnings releases. H World Group Limited (HTHT)is reporting for the quarter ending Sept... Full story
Yahoo Finance • 5 months ago
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025
WILMINGTON, Del., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2025... Full story
Yahoo Finance • 5 months ago
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a single day of treatment, using an FDA-cleared device.HOPE is one of the first Ampa deployments nationwide and is now deployed at multiple... Full story
Yahoo Finance • 6 months ago
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
Cohen and Associates has more than a decade of leadership in interventional psychiatry and Transcranial Magnetic Stimulation (TMS) Dr. Rebecca Cohen has joined HOPE as Medical DirectorImmediate expansion is planned in Western Florida and P... Full story
Yahoo Finance • 6 months ago
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
WILMINGTON, Del., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"),... Full story
Yahoo Finance • 6 months ago
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
KETAFREE™ to provide innovative, preservative-free IV ketamine formulation, eliminating toxic preservatives, in keeping with current HHS priorities to eliminate toxic preservatives from foods and drugsFiling is based on FDA interaction and... Full story
Yahoo Finance • 7 months ago
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine
Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamineGranting of Suitability Petition enables re-filing of Abbreviated New Drug Application (ANDA) for NRx’s patent... Full story
